Aspirin and the risk of prostate cancer mortality

Nature Reviews Clinical Oncology

Volumn 9, Issue 11, 2012, Pages 616-617

  La Vecchia, Carlo ^a   Bosetti, Cristina ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CYCLOOXYGENASE 2 INHIBITOR;

ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMOPROPHYLAXIS; COHORT ANALYSIS; DISEASE ACTIVITY; DRUG EFFECT; DRUG USE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; METASTASIS POTENTIAL; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; THROMBOSIS; TREATMENT RESPONSE; MALE; MORTALITY; NOTE; PROSTATE TUMOR; RISK ASSESSMENT; SURVIVAL RATE;

ANTICOAGULANTS; ASPIRIN; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL RATE;

EID: 84868197783     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.182     Document Type: Article

References (10)

1. Choe, K. S. et al. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J. Clin. Oncol. 30, 3540-3544 (2012).
2. Bambace, N. M. & Holmes, C. E. The platelet contribution to cancer progression. J. Thromb. Haemost. 9, 237-249 (2011).
3. Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. Nat. Rev. Cancer 11, 123-134 (2011).
4. Camerer, E. et al. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 104, 397-401 (2004).
5. Cuzick, J. et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 10, 501-507 (2009).
6. Rothwell, P. M. et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 379, 1591-1601 (2012).
7. Thun, M. J., Henley, S. J. & Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl Cancer Inst. 94, 252-266 (2002).
8. Brown, J. R. & DuBois, R. N. COX 2: a molecular target for colorectal cancer prevention. J. Clin. Oncol. 23, 2840-2255 (2005).
9. Bosetti, C., Rosato, V., Gallus, S. & La Vecchia, C. Aspirin and urologic cancer risk: an update. Nat. Rev. Urol. 9, 102-110 (2012).
10. Bosetti, C., Rosato, V., Gallus, S., Cuzick, J. & La Vecchia, C. Aspirin and cancer risk: a quantitative review to 2011. Ann. Oncol. 23, 1403-1415 (2012).